EU's CHMP recommends fifth H1N1 vaccine and intravenous Relenza
This article was originally published in Scrip
Executive Summary
The EU's CHMP has backed the conditional approval of Sanofi-Pasteur's adjuvanted H1N1 influenza vaccine Humenza for the prophylaxis of influenza in an officially declared pandemic situation.